Adding a Medicine to the WHO Model List of Essential Medicines

被引：13

作者：

Kishore, S. P. ^{[1
]}

Herbstman, B. J. ^{[1
]}

机构：

[1] Weill Cornell Med Coll, New York, NY USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2009年 / 85卷 / 03期

关键词：

CORONARY-HEART-DISEASE; DEVELOPING-WORLD; CARDIOVASCULAR-DISEASE; TOTAL CHOLESTEROL; METAANALYSIS; MORTALITY; STATINS; STROKE;

D O I：

10.1038/clpt.2008.258

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Although the concept of essential medicines is not new, the processes that lead to placement of these medicines on the World Health Organization Model List of Essential Medicines are not well understood. here, we describe the process by which we added a class of drugs, statins, to the Model List to help combat the growing global epidemic of cardiovascular disease.

引用

收藏

页码：237 / 239

页数：3

相关论文

共 17 条

[1]

[Anonymous], 2007, INT DRUG PRIC IND GU

[2] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].

Baigent, C ;

Keech, A ;

Kearney, PM ;

Blackwell, L ;

Buck, G ;

Pollicino, C ;

Kirby, A ;

Sourjina, T ;

Peto, R ;

Collins, R ;

Simes, J .

LANCET, 2005, 366 (9493) :1267-1278

[3] Total cholesterol and mortality in China, Poland, Russia, and the US [J].

Cai, JW ;

Pajak, A ;

Li, YH ;

Shestov, D ;

Davis, CE ;

Rywik, S ;

Li, Y ;

Deev, A ;

Tyroler, HA .

ANNALS OF EPIDEMIOLOGY, 2004, 14 (06) :399-408

[4]

*CHEM INF SERV, DIR WORLD CHEM PROD

[5]

Gaziano T, 2006, CARDIOVASCULAR DIS

[6] Cardiovascular disease in the developing world and its cost-effective management [J].

Gaziano, TA .

CIRCULATION, 2005, 112 (23) :3547-3553

[7] Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis [J].

Gaziano, Thomas A. ;

Opie, Lionel H. ;

Weinstein, Milton C. .

LANCET, 2006, 368 (9536) :679-686

[8] Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis [J].

Law, MR ;

Wald, NJ ;

Rudnicka, AR .

BRITISH MEDICAL JOURNAL, 2003, 326 (7404) :1423-1427

[9]

Matsuzawa Y, 2003, CIRC J, V67, P287

[10] Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin [J].

Mück, W ;

Unger, S ;

Kawano, K ;

Ahr, G .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (06) :583-590